[go: up one dir, main page]

AP2001002038A0 - Pharmaceutical uses of NAB1 and NAB2. - Google Patents

Pharmaceutical uses of NAB1 and NAB2.

Info

Publication number
AP2001002038A0
AP2001002038A0 APAP/P/2001/002038A AP2001002038A AP2001002038A0 AP 2001002038 A0 AP2001002038 A0 AP 2001002038A0 AP 2001002038 A AP2001002038 A AP 2001002038A AP 2001002038 A0 AP2001002038 A0 AP 2001002038A0
Authority
AP
ARIPO
Prior art keywords
nab1
nab2
pharmaceutical uses
therapyl
nabi2
Prior art date
Application number
APAP/P/2001/002038A
Other languages
English (en)
Inventor
Martin Braddock
Callum Jeffrey Campbell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9814989.1A external-priority patent/GB9814989D0/en
Priority claimed from GBGB9819826.0A external-priority patent/GB9819826D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AP2001002038A0 publication Critical patent/AP2001002038A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
APAP/P/2001/002038A 1998-07-11 1999-07-09 Pharmaceutical uses of NAB1 and NAB2. AP2001002038A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9814989.1A GB9814989D0 (en) 1998-07-11 1998-07-11 Gene therapy method
GBGB9819826.0A GB9819826D0 (en) 1998-09-12 1998-09-12 Gene therapy method
PCT/GB1999/002199 WO2000003014A1 (fr) 1998-07-11 1999-07-09 Utilisations pharmaceutiques de nab1 et nab2

Publications (1)

Publication Number Publication Date
AP2001002038A0 true AP2001002038A0 (en) 2001-03-31

Family

ID=26314007

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2001/002038A AP2001002038A0 (en) 1998-07-11 1999-07-09 Pharmaceutical uses of NAB1 and NAB2.

Country Status (22)

Country Link
EP (1) EP1097200A1 (fr)
JP (1) JP2002520020A (fr)
KR (1) KR20010071832A (fr)
CN (1) CN1317045A (fr)
AP (1) AP2001002038A0 (fr)
AU (1) AU763713B2 (fr)
BR (1) BR9912018A (fr)
CA (1) CA2336805A1 (fr)
EA (1) EA200100028A1 (fr)
EE (1) EE200100020A (fr)
HR (1) HRP20010025A2 (fr)
HU (1) HUP0102835A3 (fr)
ID (1) ID27742A (fr)
IL (1) IL140533A0 (fr)
IS (1) IS5788A (fr)
NO (1) NO20010166L (fr)
NZ (1) NZ509174A (fr)
PL (1) PL345507A1 (fr)
SK (1) SK382001A3 (fr)
TR (1) TR200100622T2 (fr)
WO (1) WO2000003014A1 (fr)
YU (1) YU1901A (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928430D0 (en) * 1999-12-01 2000-01-26 Glaxo Group Ltd Screening
US6753321B2 (en) 2000-09-15 2004-06-22 Genvec, Inc. Method of modulating neovascularization
WO2004083435A1 (fr) * 2003-03-17 2004-09-30 Julius-Maximilians-Uni Versität Würzburg Proteines nab et leur utilisation dans des applications diagnostiques et therapeutiques de maladie cardiaque

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection

Also Published As

Publication number Publication date
BR9912018A (pt) 2006-01-31
HRP20010025A2 (en) 2001-12-31
NZ509174A (en) 2003-08-29
WO2000003014A1 (fr) 2000-01-20
TR200100622T2 (tr) 2001-10-22
IS5788A (is) 2000-12-22
PL345507A1 (en) 2001-12-17
NO20010166D0 (no) 2001-01-10
AU763713B2 (en) 2003-07-31
EP1097200A1 (fr) 2001-05-09
KR20010071832A (ko) 2001-07-31
HUP0102835A2 (hu) 2001-11-28
SK382001A3 (en) 2001-09-11
EA200100028A1 (ru) 2001-08-27
IL140533A0 (en) 2002-02-10
CA2336805A1 (fr) 2000-01-20
AU4791499A (en) 2000-02-01
JP2002520020A (ja) 2002-07-09
CN1317045A (zh) 2001-10-10
NO20010166L (no) 2001-03-06
YU1901A (sh) 2005-06-10
EE200100020A (et) 2002-06-17
ID27742A (id) 2001-04-26
HUP0102835A3 (en) 2003-09-29

Similar Documents

Publication Publication Date Title
NZ271756A (en) Human macrophage inflammatory proteins and coding sequences, their production and use
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
DE69811371D1 (de) Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung
ATE451929T1 (de) Von casein abgeleitete peptide und deren anwendung für die therapie
EP2679235A3 (fr) Peptides et molécules associées qui modulent l'activité du facteur de croissance nerveuse
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
NZ508505A (en) Treatment of wounds using an Egr-1 transcription factor polypeptide
EP0815202A4 (fr) Inhibiteur tissulaire de metalloproteases-4 de provenance humaine
NZ515964A (en) A method for the prophylaxis and/or treatment of medical disorders
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
AU3386100A (en) Anti-tnfalpha antibodies in therapy of asthma
DE60015560D1 (de) Verwendung von aminosäure zur herstellung von arzneimitteln zur behandlung von insulinresistenz
WO2006048450A3 (fr) Nouveaux peptides utiles dans le traitement de l'obesite
AP2001002038A0 (en) Pharmaceutical uses of NAB1 and NAB2.
WO2006048452A3 (fr) Nouveaux peptides utiles dans le traitement de l'obesite
WO2003093419A3 (fr) Prevention de lymphoedeme secondaire avec un adn de vegf-d
WO2002088180A3 (fr) Utilisation de polypeptides alpha 1-antichymotrypsine ou d'acides nucleiques codant ces derniers, ou bien d'une cellule qui exprime un polypeptide act, ou d'un d'acide nucleique codant ce dernier, pour traiter et/ou prevenir les plaies se cicatrisant difficilement associees au diabete et/ou aux arteres et pour identifier d
WO1998054209A3 (fr) Mafa humaine
ZA961419B (en) Human DNase I variants.
WO2002083060A3 (fr) Utilisation du transporteur atb0,+ d'acides amines comme systeme d'administration de medicaments et promedicaments
FI954889A0 (fi) Proteiini, jolla on TPO-aktiviteetti
WO2000026362A3 (fr) Proteines de la famille de la stomatine et leur utilisation comme proteines cibles pour le traitement de la douleur
CA2601208A1 (fr) Procede de prevention ou de traitement du diabete
ATE403434T1 (de) Peptide zur modulierung der knorpelhomöostase